$1,318.00
This Market Spotlight report covers the Zika virus market, comprising key pipeline therapies, clinical trials, probability of success, epidemiology, and licensing and acquisition deals.
This Market Spotlight report covers the Zika virus market, comprising key pipeline therapies, clinical trials, probability of success, epidemiology, and licensing and acquisition deals.
Key Takeaways
CONTENTS
5 OVERVIEW
6 KEY TAKEAWAYS
7 DISEASE BACKGROUND
8 TREATMENT
8 Vaccines
8 Therapeutics
10 EPIDEMIOLOGY
11 PIPELINE DRUGS
17 KEY REGULATORY EVENTS
17 FDA Revokes Emergency Authorization On Ebola, Zika Tests
18 PROBABILITY OF SUCCESS
19 CLINICAL TRIAL LANDSCAPE
20 Sponsors by status
21 Sponsors by phase
23 BIBLIOGRAPHY
24 APPENDIX
LIST OF FIGURES
10 Figure 1: Recent epidemiological updates
10 Figure 2: Zika cases timeline
11 Figure 3: Overview of pipeline drugs for Zika virus in the US
12 Figure 4: Pipeline drugs for Zika virus, by company
12 Figure 5: Pipeline drugs for Zika virus, by drug type
12 Figure 6: Pipeline drugs for Zika virus, by classification
18 Figure 7: Probability of success in the antiviral pipeline
19 Figure 8: Clinical trials in Zika virus
19 Figure 9: Top 10 drugs for clinical trials in Zika virus
20 Figure 10: Top 10 companies for clinical trials in Zika virus
20 Figure 11: Zika virus trial locations
21 Figure 12: Zika virus trials status
22 Figure 13: Zika virus trials sponsors, by phase
LIST OF TABLES
14 Table 1: Pipeline drugs for Zika virus in the US
© Informa UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email pharma@informabi.com for further help or assistance.
Sign up to the Pharma Intelligence Report Store Newsletter to get the latest blogs, news, reports and discounts!